RITALIN LA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ritalin La, and what generic alternatives are available?
Ritalin La is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ritalin La
A generic version of RITALIN LA was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RITALIN LA?
- What are the global sales for RITALIN LA?
- What is Average Wholesale Price for RITALIN LA?
Summary for RITALIN LA
Recent Clinical Trials for RITALIN LA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Phase 4 |
University of Florida | Early Phase 1 |
University of Zurich | Phase 1 |
Pharmacology for RITALIN LA
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Paragraph IV (Patent) Challenges for RITALIN LA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RITALIN LA | Extended-release Capsules | methylphenidate hydrochloride | 10 mg | 021284 | 1 | 2007-05-21 |
RITALIN LA | Extended-release Capsules | methylphenidate hydrochloride | 20 mg, 30 mg and 40 mg | 021284 | 2006-08-21 |
US Patents and Regulatory Information for RITALIN LA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sandoz | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-005 | Oct 27, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RITALIN LA
International Patents for RITALIN LA
See the table below for patents covering RITALIN LA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 9914977 | Composição multiparticulada de liberação modificada | ⤷ Sign Up |
Brazil | PI0705488 | ⤷ Sign Up | |
Australia | 2007260822 | ⤷ Sign Up | |
China | 101259106 | ⤷ Sign Up | |
Norway | 20090158 | ⤷ Sign Up | |
Israel | 179379 | MULTIPARTICULATE MODIFIED RELEASE COMPOSITION | ⤷ Sign Up |
Slovakia | 287674 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |